Drug maker Alteogen has announced that it will file an Investigational New Drug (IND) application with the FDA for its proposed biosimilar aflibercept (ALT-L9), an anti–vascular endothelial growth factor therapy referencing Regeneron’s Eylea, during 2018.
Drug maker Alteogen has announced that it will file an Investigational New Drug (IND) application with the FDA for its proposed biosimilar aflibercept (ALT-L9), an anti—vascular endothelial growth factor therapy referencing Regeneron’s Eylea, during 2018.
According to The Investor, Alteogen, based in the Republic of Korea, has completed US-based preclinical studies of ALT-L9 that demonstrated that the proposed biosimilar is similar to the reference, and says that it will present official preclinical data within the next 3 months. The preclinical toxicity study was conducted in animals during a 13-week period. Pulse News reports that the biosimilar developer will initiate global clinical trials soon after it receives an official report on the animal test results.
“We plan to present the official analysis report of the preclinical results at an academic conference and expect licensing-out negotiations to be accelerated,” Alteogen CEO, Soon-Jae Park, said in a statement.
According to Alteogen, ALT-L9 is also more resilient to high temperatures, and has a longer shelf life, than the originator drug because of the biosimilar developer’s formulation technology.
The 1 additional biosimilar in Alteogen’s pipeline is a proposed trastuzumab molecule, ALT-02. The drug reportedly underwent phase 1 studies in Canada in 2016, and phase 3 clinical trials for the drug were slated to begin in 2017. The drug maker also reports that it is developing a so-called “biobetter” (a therapy that has resulted from intentionally altering a biologic product in order to improve its clinical effects) of a monoclonal antibody using the company’s proprietary antibody-drug conjugate technology.
Alteogen is not the first biosimilar developer to announce progress on an aflibercept product during this month; Momenta Pharmaceuticals and its partner Mylan announced on January 3 that they will initiate a pivotal clinical trial of M710, in 2018. On January 8, biosimilar developer Coherus announced at the 36th Annual J.P. Morgan Healthcare Conference that its CHS-2020 has initiated preclinical development.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.